Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Activation of caspases and proteolytic cleavage of caspase substrates is an early, critical cellular event in several
neurodegenerative diseases. Caspase-6 (casp6) in particular has emerged as an important player. Casp6 has been shown to
function as an initiator caspase through its ability to cleave and activate other caspases and activation of casp6 is observed prior
to the clinical and pathological diagnosis of both Alzheimer disease (AD) and Huntington disease. In support of this, recent
studies suggest caspase activation precedes and leads to tangle formation in AD. This includes an important role for casp6 in
axonal degeneration and memory impairment, further underscoring the importance of this protease in neurodegenerative
pathways. Despite the wealth of data regarding casp6 in human AD brain, only limited details are available in mouse models
which enable a detailed assessment of all aspects of neurodegeneration including delineation of important early primary
events. Similar to human AD brain, we detect early activation of casp6 in a pre-symptomatic mouse model of AD, prior to
obvious degeneration and activation of other caspases. Furthermore, through yeast-2-hybrid studies, we have identified, and
validated, novel casp6 interactors STK3 and DAXX. Assessment of AD murine tissues reveals increases in DAXX and STK3 are
detected early and alterations in post translational modifications observed. Casp6 now links STK3 and DAXX with AKT, JNK
and histones in the pathogenesis of AD and highlights an early role for these substrates in neurodegenerative pathways. These
data provide strong support for casp6 as a potential target for therapeutic intervention in AD.
Biography
Rona K Graham completed her PhD in 2006 and did her postdoctoral studies at the University of BC. She is now an Assistant Professor at the University of
Sherbrooke and holds the Canada Research Chair in Neurodegenerative disease. Dr Graham has more than 45 publications, many in high impact journals, is
editorial review board member for Frontiers in Genetics Disorders and is involved in numerous outreach activities in the community.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals